Medicago: PhII avian flu vax trial successful

Canada's Medicago says the company's Phase II trial of its vaccine for avian flu elicited a solid immune response and was found to be safe and well tolerated. Notably, the vaccine was equally effective in older and younger subjects, which CEO Andy Sheldon could be a key selling point for the shot.

The vaccine is based on Medicago's manufacturing technologies and virus-like particles (VLPs), that allow the developer to rapidly produce more effective vaccines. Medicago is on the verge of opening a 90,000-square-foot facility in Research Triangle Park, NC to help manufacture VLP plant-based vaccine technology. The developer expects to have commercial capacity by this fall.

"...[W]e believe these results further support the effectiveness of our rapid plant-based vaccine platform and the development of our seasonal flu vaccine candidate which we intend to proceed with a U.S. clinical trial in the second half of the year," noted Sheldon in a release.

- here's Medicago's release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.